Lilly drug slows Alzheimer’s progression by 35% in trial
An experimental Alzheimer’s drug developed by New England Council member, Eli Lilly, shows great promise after a late-stage clinical trial displaying that it slowed cognitive decline by 35%, raising hopes for a second effective treatment.
Eli Lilly announced the major success of the late-stage clinical trial of the drug, donanemab. This drug met all primary and secondary goals of the trial and, most importantly, slowed the progression of Alzheimer’s by 35% to 36% compared to a placebo, in 1,182 people diagnosed with early-stage disease based on scans. The company said it plans to file for traditional U.S. approval by the end of June and with regulators from other countries shortly thereafter.
“These are the strongest phase 3 data for an Alzheimer’s treatment to date. This further underscores the inflection point we are at for the Alzheimer’s field,” said Maria Carrillo, chief science officer for the Alzheimer’s Association.
The New England Council commends Eli Lilly’s continued fight against Alzheimer’s.
Read more from the New Hampshire Union Leader.